Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

September 25, 2018

Viracta Announces Scientific Advisory Board Formation - San Diego, CA, September 25, 2018 - Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, announced the formation of its inaugural Scientific Advisory Board. Read More

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

Events

October 11-12, 2018

David Slack, Viracta’s Chief Business Officer, will participate in the BioNetwork Partnering Summit, Laguna Niguel, CA, October 11-12. Read More

Recent News

September 25, 2018

Viracta Announces Scientific Advisory Board Formation - San Diego, CA, September 25, 2018 - Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, announced the formation of its inaugural Scientific Advisory Board. Read More

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

Events

October 11-12, 2018

David Slack, Viracta’s Chief Business Officer, will participate in the BioNetwork Partnering Summit, Laguna Niguel, CA, October 11-12. Read More